Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 494-501

  Kang, B W ^a   Seo, A N ^b   Yoon, S ^a   Bae, H I ^b   Jeon, S W ^b   Kwon, O K ^b   Chung, H Y ^b   Yu, W ^b   Kang, H ^c   Kim, Jong G ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Epstein Barr virus associated gastric cancer; Gastric cancer; Host immune reaction; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE FREE SURVIVAL; ENDOSCOPIC SUBMUCOSAL DISSECTION; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; LYMPHATIC INVASION; LYMPHOEPITHELIOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR LOCALIZATION; VENOUS INVASION; VERY ELDERLY; ADENOCARCINOMA; EPSTEIN BARR VIRUS INFECTION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; STOMACH NEOPLASMS; TREATMENT OUTCOME; VIROLOGY;

TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84959884607     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv610     Document Type: Article

References (31)

1. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009; 137: 824-833.
2. Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol 2015; 235: 323-333.
3. Kim SY, Park C, Kim H-J et al. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology 2015; 148: 137-147. e139.
4. Song HJ, Srivastava A, Lee J et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 2010; 139: 84-92. e82.
5. Kim J, Nam K, Ahn S-H et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 2016; 19: 42-52.
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209.
7. Chang WJ, Du Y, Zhao X et al. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 2014; 20: 4586-4596.
8. Baldan V, Griffiths R, Hawkins RE, Gilham DE. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br J Cancer 2015; 112: 1510-1518.
9. Gasparri ML, Attar R, Palaia I et al. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev 2015; 16: 3635-3638.
10. Lynch HT, Lanspa SJ, Snyder CL, Drescher KM. Microsatellite instability, diseasefree survival and role of tumour infiltrating lymphocytes (Invited editorial on 'Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicenter study'). Eur J Cancer 2015; 51: 922-924.
11. Wang B, Wu S, Zeng H et al. CD103(+)tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol 2015; 194: 556-562.
12. Fortes C, Mastroeni S, Mannooranparampil TJ et al. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Res 2015; 25: 306-311.
13. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
14. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
15. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966.
16. Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumorinfiltrating lymphocytes on residual disease after primary chemotherapy for triplenegative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25: 611-618.
17. Lee HE, Chae SW, Lee YJ et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008; 99: 1704-1711.
18. Lee K, Hwang H, Nam KT. Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. Gut Liver 2014; 8: 131-139.
19. Grogg KL, Lohse CM, Pankratz VS et al. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003; 16: 641-651.
20. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer-Verlag 2010.
21. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005; 2: 416-422.
22. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
23. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System, 4th edition. Lyon: IARC press Switzerland. World Health Organization 2010.
24. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
25. Dieci MV, Mathieu MC, Guarneri V et al. Prognostic and predictive value of tumor infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 2015; 26: 1698-1704.
26. Feng Y, Shen J, Gao Y et al. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget 2015; 6: 11139-11149.
27. Zitvogel L, Kroemer G. The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ 2008; 15: 1-2.
28. Ishigami S, Natsugoe S, Tokuda K et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88: 577-583.
29. Song HJ, Kim KM. Pathology of Epstein-Barr virus-associated gastric carcinoma and its relationship to prognosis. Gut Liver 2011; 5: 143-148.
30. Chung GT, Lou WP, Chow C et al. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. J Pathol 2013; 231: 311-322.
31. Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol 2015; 16: 17.